The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 33, Issue 3, 2015, Pages 321-329

  Feuchtenberger, Martin ^a   Kleinert, Stefan ^a   Scharbatke, Eva Christina ^a   Gnann, Holger ^b   Behrens, Frank ^c   Wittig, Bianca M ^d   Greger, Gerd ^d   Tony, Hans Peter ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Biostatistics GKM Gesellschaft für Therapieforschung mbH ^*  (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d ABBVIE INC   (United States)

Author keywords

Adalimumab; Anti rheumatic agents; Biologic therapy; Rheumatoid arthritis; Treatment effectiveness; Treatment outcome; Tumour necrosis factor alpha

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL STATUS; FUNKTIONSFRAGEBOGEN HANNOVER FUNCTIONAL ABILITY SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT HISTORY OF THERAPY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT OUTCOME; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; GERMANY; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; SEVERITY OF ILLNESS INDEX; TIME FACTOR;

ADALIMUMAB; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84939549177     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. SMOLEN JS, ALETAHA D, BIJLSMA JWJ et al.: Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-7.
2. SCHETT G, STACH C, ZWERINA J, VOLL R, MANGER B: How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis Rheum 2008; 58: 2936-48.
3. BREEDVELD FC, WEISMAN MH, KAVAN-AUGH AF et al.: The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treat-ment. Arthritis Rheum 2006; 54: 26-37.
4. BURMESTER GR, MARIETTE X, MONTECUCCO C et al.: Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007; 66: 732-9.
5. CHEN YF, JOBANPUTRA P, BARTON P et al.: A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006; 10: 1-266.
6. FURST DE, SCHIFF MH, FLEISCHMANN RM et al.: Adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003; 30: 2563-71.
7. KEYSTONE EC, KAVANAUGH AF, SHARP JT et al.: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheuma-toid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400-11.
8. Van de PUTTE LBA, ATKINS C, MALAISE M et al.: Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004; 63: 508-16.
9. WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
10. WEINBLATT ME, KEYSTONE EC, FURST DE, KAVANAUGH AF, CHARTASH EK, SEGU-RADO OG: Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 2006; 65: 753-9.
11. Humira® (adalimumab) summary of product characteristics. Abbott Laboratories Ltd., United Kingdom. May 2010. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000481/WC500050870.pdf Accessed January 23, 2012.
12. SILVERMAN SL: From randomized controlled trials to observational studies. Am J Med 2009; 122: 114-20.
13. KLEINERT S, TONY H-P, KRAUSE A et al.: Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German non-interventional observational study. Rheumatol Int 2012; 32: 2759-67.
14. Vander CRUYSSEN B, Van LOOY S, WYNS B et al.: DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid patients: validation of the DAS28 score in patients under infliximab treatment. Arthritis Res Ther 2005; 7: R1063-71.
15. RASPE HH, HAGEDORN U, KOHLMANN T, MATTUSSEK S: Der Funktionsfragebog-en Hannover (FFbH): Ein Instrument zur Funk-tionsdiagnostik bei polyartikulären Gelenkerkrankungen. In SIEGRIST J (Ed.): Wohnort-nahe Betreuung Rheumakranker. Ergebnisse sozialwissenschaftlicher Evaluation eines Modellversuchs. Stuttgart, Schattauer 1999: S164-82.
16. LAUTENSCHLäGER J, MAU W, KOHLMANN T et al.: Evaluation einer deutschen Version des Health Assessment Questionnaires (HAQ) und des Funktionsfragebogens Hannover (FFbH). [Comparative evaluation of a German version of the Health Assessment Questionnaire and the Hannover Functional Capacity Questionnaire]. Z Rheumatol 1997; 56: 144-55.
17. Van GESTEL AM, PREVOO MLL, VAN'T HOF MA, RIJSWIK MH, de PUTTE LBA, RIEL PLCM: Development and validation of the European League Against Rheumatism response criteria. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism response criteria. Arthritis Rheum 1996; 39: 34-40.
18. FRANSEN J, CREEMERS MCW, Van RIEL PL: Remission in rheumatoid arthritis: agreement of the Disease Activity Score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004; 43: 1252-5.
19. BEHRENS F, TONY H-P, ALTEN R et al.: Development and validation of a new DAS28-based treatment response criterion for rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013; 65: 1608-16.
20. LISTING J, STRANGFELD A, RAU R et al.: Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low-results from RABBIT, the German biologics register. Arthritis Res Ther 2006; 8: R66.
21. WOOLSON RF: Multiple linear regression. In WOOLSON RF (Ed.): Statistical Methods for the Analysis of Biomedical Data. New York, John Wiley & Sons, Inc. 1987: 295-300.
22. EMERY P, SEBBA A, HUIZINGA TWJ: Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis 2013; 72: 1897-904.
23. BOMBARDIERI S, RUIZ AA, FARDELLONE P et al.: Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) 2007; 46: 1191-9.
24. NAVARRO-SARABIA F, RUIZ-MONTESINOS D, HERNANDEZ B et al.: DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists. BMC Musculoskelet Disord 2009; 10: 91.
25. KARLSSON JA, KRISTENSEN LE, KAPETA-NOVIC MC, GüLFE A, SAXNE T, GEBOREK P: Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 2008; 47: 507-13.
26. SOLAU-GERVAIS E, LAXENAIRE N, CORTET B, DUBUCQUOI S, DUQUESNOY B, FLIPO RM: Lack of efficacy of a third tumour necrosis factor α antagonist after failure of a soluble receptor and a monoclonal antibody. Rheumatology (Oxford) 2006; 45: 1121-4.
27. RENDAS-BAUM R, WALLENSTEIN GV, KONCZ T et al.: Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors. Arthritis Res Ther 2011; 13: R25.
28. WAKABAYASHI H, OKA H, NISHIOKA Y, HASEGAWA M, SUDO A, NISHIOKA K: Do biologics-naive patients with rheumatoid arthritis respond better to tocilizumab than patients for whom anti-TNF agents have failed?. A retrospective study. Clin Exp Rheumatol 2011; 29: 314-7.
29. NARVAEZ J, DíAZ-TORNé C, RUIZ JM et al.: Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDS. Clin Exp Rheumatol 2011; 29: 991-7.
30. GOMEZ-REINO JJ, CARMONA L, BIOBADASER GROUP: Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006; 8: R29.
31. CAPORALI R, SARZI-PUTTINI P, ATZENI F et al.: Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry. Autoimmun Rev 2010; 9: 465-9.